Phase 3 Long COVID Trial, Recruiting NCT05943821 Sponsor: Poznan University of Medical Sciences Condition: Long COVID
Back to Long Covid

Phase 3 Long COVID Trial, Recruiting

NCT05943821
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 40 and 70 years old.
  • You are willing to give your agreement (informed consent) to take part in the study.
  • A blood test taken in the last six months showed your uric acid level was above 5 mg/dl.
  • You meet at least one of the following signs of high or very high heart and blood vessel risk:
    • A calculation of your 10-year risk of dying from a heart or blood vessel problem is above 2.5% (if you are under 50) or 5% or more (if you are 50 or older), based on a specific risk scoring tool (confirm with trial site)
    • You have been diagnosed with a heart or blood vessel condition such as a stroke, mini-stroke (TIA), brain bleed, mild-to-moderate heart failure (not caused by blocked heart arteries), peripheral artery disease, or atrial fibrillation
    • You have diabetes or high blood pressure that has caused damage to organs, shown by any of the following: stiff arteries, thickening of the heart wall, a small amount of protein leaking into your urine, or reduced blood flow to your legs (confirm with trial site)

Who may not be able to join:

  • You are currently taking allopurinol, febuxostat, or any other medication to lower uric acid levels.
  • You have a medical reason why you cannot take allopurinol.
  • You are pregnant, breastfeeding, or planning to become pregnant during the study period.
  • You are currently taking hormone therapy that contains oestrogens.
  • You have had an active cancer diagnosis in the last five years (with some exceptions for certain localised tumours — confirm with trial site).
  • Your blood pressure is very poorly controlled (average reading of 180/110 mmHg or higher in home measurements in the week before screening), even while taking blood pressure medication.
  • Your kidneys are not working well enough, based on a specific kidney function measurement falling below a certain level (confirm with trial site).
  • You have an underactive or overactive thyroid that is not currently well managed with treatment.
  • You have confirmed coronary artery disease, such as a previous heart attack, a procedure to open blocked heart arteries, or confirmed artery blockages found on a scan.
  • You have severe heart failure (classified as NYHA class III or IV — confirm with trial site).
  • You are currently taking azathioprine, mercaptopurine, or cyclosporin.
  • You have taken part in another clinical trial of a medicine or medical device within the last three months (or longer, depending on the medication involved — confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Andrzej Tykarski, Prof MD, Poznan University of Medical Sciences

Phone: 0048618546274

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Poznan University of Medical Sciences
Registry
ClinicalTrials.gov
Start date
1 September 2023
Est. completion
31 July 2028

Where this trial is recruiting

🇵🇱 Poland

Primary endpoints

The occurrence of a major adverse cardiovascular event (MACE)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov